The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RELATIVITY-020: Intracranial (IC) activity of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with PD-(L)1 refractory melanoma with melanoma brain metastases (MBM).
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)
 
F. Hodi
Employment - Dana-Farber Cancer Institute
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Apricity Health; Bicara Therapeutics; Pionyr; Torque
Consulting or Advisory Role - 92Bio; AstraZeneca; Bioentre; Bristol-Myers Squibb; Catalym; Checkpoint THerapeutics; Compass Therapeutics; Corner Therapeutics; Curis; Genentech/Roche; Gossamer Bio; Immunocore; Iovance Biotherapeutics; Kairos Therapeutics; Merck Sharp & Dohme; Novartis; Pliant; Rheos Medicines; Solu Therapeutics; Vir biotechnology; Zumutor Biologics
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Evan Lipson
Stock and Other Ownership Interests - Iovance Biotherapeutics
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; CareDX; HUYA Bioscience International; Immunocore; Instil Bio; IO Biotech; Merck; Merck KGaA; Nektar; Novartis; OncoSec; Pfizer; Rain Therapeutics; Regeneron; Replimune; Sun Pharma; Syneos Health
Research Funding - 1104Health (Inst); Bristol-Myers Squibb (Inst); Haystack Oncology (Inst); Merck (Inst); Regeneron (Inst); Sanofi (Inst)
 
Eva Muñoz Couselo
Honoraria - BMS; Immunocore; MSD; Novartis; Pierre Fabre; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Immunocore; Menarini; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pierre Fabre; Sanofi
 
James Larkin
Honoraria - Bristol-Myers Squibb; Cancer Research UK; Eisai; GlaxoSmithKline; Gynavax; Incyte; iOnctura; Merck Serono; Novartis; Pfizer; Roche; touchEXPERTS; touchIME
Consulting or Advisory Role - Apple Tree Partners; Boston Biomedical; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Immunocore; Incyte; iOnctura; Iovance Biotherapeutics; Ipsen; Merck Serono; Novartis; Pfizer; Roche; YKT Corporation
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; ESMO; GlaxoSmithKline; Roche/Genentech
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre; UCB
Consulting or Advisory Role - Bristol Meyer Squib; Iovance Biotherapeutics; MSD Oncology; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cytovation (Inst); Daiichi Sankyo Europe GmbH (Inst); Day One Biopharmaceuticals (Inst); DOT therapeutics (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); IFX (Inst); Immunocore (Inst); Incyte (Inst); IO Biotech (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Kinnate Biopharma (Inst); Merck (Inst); Microbiotica (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Sairopa (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre
 
Luke Mantle
No Relationships to Disclose
 
Mark Semaan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Julius Strauss
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ruiyun Jiang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Diederik Grootendorst
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Divya Patel
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; Immunocore; Italfarmaco; Lunaphore Technologies; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre; Replimune